The current results indicated that failure to obtain a PSA-CR ( PSA 0.3 ng/mL ) after short-term hormone therapy and external-beam radiotherapy appears to be an independent predictor of unfavorable outcomes and could help identify patients who may benefit from the addition of long-term androgen ablation .
